NCT07072039 Evaluation of the Paramedic Evaluation for Acute COPD Exacerbation
| NCT ID | NCT07072039 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Massachusetts, Worcester |
| Condition | COPD (Chronic Obstructive Pulmonary Disease) |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2029-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-10-01 with a primary completion date of 2029-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic Obstructive Pulmonary Disease (COPD) is a serious lung condition that affects millions of people in the United States. Each year, it leads to about 150,000 deaths, nearly 900,000 emergency room visits, and 700,000 hospital stays. When COPD symptoms suddenly get worse-called an exacerbation-it can seriously harm a person's quality of life and often requires emergency care. Treating these flare-ups early can help prevent hospital visits, but right now, there aren't many good ways to make sure people get care quickly. Mobile Integrated Health (MIH) programs send specially trained paramedics, guided remotely by doctors, to care for patients in their homes. This approach could help people with COPD get faster, more effective care without needing to go to the hospital. In this project, the investigators are testing a new program called PEACE (Paramedic Evaluation for Acute COPD Exacerbation). The PEACE program sends community paramedics to patients' homes-when needed and in partnership with their regular doctors-to manage worsening COPD symptoms early. The study team will adapt the PEACE program to meet the needs of adults living at home with moderate to severe COPD, gather feedback from patients and healthcare providers, and run a small pilot study to see if the program is practical and helpful.
Eligibility Criteria
Inclusion Criteria: 1. Diagnosis of COPD 2. At least one COPD exacerbation resulting in ED utilization in the six months prior to enrollment 3. COPD GOLD Score letter designation of B, C, or D 4. Receives care in the UMass Memorial Medical Center Pulmonary Clinic or Benedict Family Health Clinic 5. Over 18 years of age 6. Speaks English 7. Resides in the geographical catchment area allowed by the UMass Memorial Medical Center MIH Program's license Exclusion Criteria: 1. No prior diagnosis of COPD 2. Under 18 years of age 3. Does not speak English 4. Pregnancy 5. Cannot provide informed consent
Contact & Investigator
Laurel O'Connor, MD, MSc
PRINCIPAL INVESTIGATOR
University of Massachusetts, Worcester
Frequently Asked Questions
Who can join the NCT07072039 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying COPD (Chronic Obstructive Pulmonary Disease). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07072039 currently recruiting?
Yes, NCT07072039 is actively recruiting participants. Contact the research team at laurel.oconnor@umassmed.edu for enrollment information.
Where is the NCT07072039 trial being conducted?
This trial is being conducted at Worcester, United States.
Who is sponsoring the NCT07072039 clinical trial?
NCT07072039 is sponsored by University of Massachusetts, Worcester. The principal investigator is Laurel O'Connor, MD, MSc at University of Massachusetts, Worcester. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.